A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...

Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immen ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Heston Blumenthal has revealed that he is taking the weight-loss drug Wegovy. The celebrity chef admitted his use of the drug ...

GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

But the study warns the drugs may also cause muscle loss, which is essential for strength, posture, and long-term health. Too much lean mass loss, researchers say, could increase the risk of heart ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...